Literature DB >> 15879440

Faecal calprotectin in the assessment of Crohn's disease activity.

D R Gaya1, T D B Lyon, A Duncan, J B Neilly, S Han, J Howell, C Liddell, A J Stanley, A J Morris, J F Mackenzie.   

Abstract

BACKGROUND: Clinical and laboratory assessment of activity in Crohn's disease (CD) correlate poorly with endoscopic findings. Calprotectin is a calcium-binding protein abundant in neutrophil cytosol, and extremely stable in faeces. Faecal calprotectin (FC) is an excellent surrogate marker of neutrophil influx into the bowel lumen. AIM: To assess whether FC concentration from a spot stool sample reliably detects active inflammation in patients with CD.
DESIGN: Cross-sectional comparative study.
METHODS: Subjects had a previously confirmed diagnosis of CD and were suspected on clinical grounds to be in the midst of a relapse. Thirty-five entered the study; they underwent radiolabelled white cell scanning (WCS) and had a stool sample collected for calprotectin measurement on the same day. A Crohn's disease activity index (CDAI) was also calculated for each. The WCS scans were scored at six standard sites to give a mean total, 'extent', 'severity' and 'combined extent and severity' scores.
RESULTS: FC was significantly and positively correlated with mean total (r = 0.73, p < 0.001), 'extent' (r = 0.71, p < 0.001), 'severity' (r = 0.64, p < 0.001) and combined 'extent and severity' WCS scores (r = 0.71, p < 0.001). A cut-off of faecal calprotectin > 100 microg/g gave a sensitivity of 80%, specificity of 67%, positive predictive value of 87% and a negative predictive value of 64% in identifying those with and without any inflammation on WCS. There was, however, no significant correlation between CDAI and mean total WCS score (r = 0.21, p = 0.24), nor between CDAI and FC (r = 0.33, p = 0.06). DISCUSSION: While the CDAI does not accurately reflect inflammatory activity in CD, a one-off FC reliably detects the presence or absence of intestinal inflammation in adult patients with CD, compared to WCS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879440     DOI: 10.1093/qjmed/hci069

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  19 in total

1.  Fecal Calprotectin: Diagnostic Accuracy of the Immunochromatographic CalFast Assay in a Pediatric Population.

Authors:  Oriano Radillo; Lorella Pascolo; Stefano Martelossi; Sara Dal Bo; Alessandro Ventura
Journal:  J Clin Lab Anal       Date:  2016-02-15       Impact factor: 2.352

2.  Clinical significance of inflammatory markers.

Authors:  Bincy P Abraham; Selvi Thirumurthi
Journal:  Curr Gastroenterol Rep       Date:  2009-10

Review 3.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

4.  Utility of faecal calprotectin analysis in adult inflammatory bowel disease.

Authors:  Lyn A Smith; Daniel R Gaya
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

5.  The Circulating Level of Soluble Receptor for Advanced Glycation End Products Displays Different Patterns in Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Study.

Authors:  Rachele Ciccocioppo; Venerina Imbesi; Elena Betti; Vincenzo Boccaccio; Peter Kruzliak; Alessandra Gallia; Giuseppina Cristina Cangemi; Gabriella Carnevale Maffe; Alessandro Vanoli; Serena Merante; Mara De Amici; Colomba Falcone; Catherine Klersy; Gino Roberto Corazza
Journal:  Dig Dis Sci       Date:  2015-03-11       Impact factor: 3.199

6.  Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease.

Authors:  Renata D'Incà; Elisabetta Dal Pont; Vincenza Di Leo; Antonio Ferronato; Walter Fries; Maria Grazia Vettorato; Diego Martines; Giacomo Carlo Sturniolo
Journal:  Int J Colorectal Dis       Date:  2006-07-13       Impact factor: 2.571

Review 7.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

8.  Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease.

Authors:  Tomoki Aomatsu; Atsushi Yoden; Kyoichi Matsumoto; Emi Kimura; Keisuke Inoue; Akira Andoh; Hiroshi Tamai
Journal:  Dig Dis Sci       Date:  2011-03-11       Impact factor: 3.199

9.  RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.

Authors:  Peter A Anton; Ross D Cranston; Angela Kashuba; Craig W Hendrix; Namandjé N Bumpus; Nicola Richardson-Harman; Julie Elliott; Laura Janocko; Elena Khanukhova; Robert Dennis; William G Cumberland; Chuan Ju; Alex Carballo-Diéguez; Christine Mauck; Ian McGowan
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-09       Impact factor: 2.205

10.  Detailed Multi-Dimensional Assessment of Fatigue in Inflammatory Bowel Disease.

Authors:  Kristina Aluzaite; Rashid Al-Mandhari; Hamish Osborne; Christine Ho; Merrilee Williams; Marie-Michelle Sullivan; Catherine E Hobbs; Michael Schultz
Journal:  Inflamm Intest Dis       Date:  2019-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.